Late-Stage Diabetes Study Sets the Stage for Lexicon Pharma

Health and Healthcare

Published: July 21, 2020 10:56 am

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes. Overall, all the studies met their primary endpoints.

In terms of the specifics, the topline data comes from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The company was quick to note that the final results of these studies will be preserved for upcoming medical congresses and publications.

Again all four Phase 3 sotagliflozin studies met their primary objectives of lowering A1C in patients with type 2 diabetes. The observed safety profile of sotagliflozin in these studies was generally consistent with that of approved SGLT2 inhibitors.

In terms of treatment related effects, diarrhea, which is consistent with gastrointestinal SGLT1 inhibition, was generally more common on sotagliflozin than placebo, although it was not a meaningful cause of treatment discontinuation. Genital mycotic infections were dose-related. The absolute increase in the incidence of genital mycotic infections over placebo ranged from 0.0% to 3.7% in studies of the 200 mg dose and from 3.2% to 6.3% in studies of the 400 mg dose.

Additionally, in one study, sotagliflozin showed less hypoglycemia than glimepiride, and in the other three studies, the incidences of hypoglycemia in patients on sotagliflozin were similar to those on placebo.

Looking ahead, the company does not intend to pursue any regulatory approvals of sotagliflozin for type 2 diabetes in the absence of a strategic partnership for the commercialization of sotagliflozin in such indication.

Lexicon Pharma stock traded up about 11% on Tuesday to $2.34, in a 52-week range of $1.13 to $5.76. The consensus price target is $4.70.

ALSO READ: Americans Are Driving This Summer Instead of Flying: 4 Stocks Could Be Big Winners

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps